APLS
Apellis Pharmaceuticals Inc

3,699
Mkt Cap
$3.12B
Volume
1.81M
52W High
$35.71
52W Low
$16.10
PE Ratio
83.13
APLS Fundamentals
Price
$24.97
Prev Close
$24.68
Open
$24.66
50D MA
$23.03
Beta
1.02
Avg. Volume
2.58M
EPS (Annual)
-$1.60
P/B
7.78
Rev/Employee
$1.1M
Loading...
Loading...
News
all
press releases
Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS
Bank of Nova Scotia acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·15h ago
News Placeholder
More News
News Placeholder
Ossiam Takes $9.62 Million Position in Apellis Pharmaceuticals, Inc. $APLS
Ossiam bought a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·2d ago
News Placeholder
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS
Marshall Wace LLP lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 11,373.8% during the 2nd quarter, according to its most recent 13F filing with the...
MarketBeat·5d ago
News Placeholder
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS
Norges Bank purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·5d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2% - Still a Buy?
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2% - Here's Why...
MarketBeat·5d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been given an average rating of "Hold" by the eighteen research firms that are currently covering the stock, MarketBeat reports. Two...
MarketBeat·6d ago
News Placeholder
Schroder Investment Management Group Grows Position in Apellis Pharmaceuticals, Inc. $APLS
Schroder Investment Management Group grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 91.9% in the second quarter, according to its most recent disclosure...
MarketBeat·6d ago
News Placeholder
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·7d ago
News Placeholder
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS
Prudential Financial Inc. lowered its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 29.3% in the 2nd quarter, according to its most recent Form 13F filing with the...
MarketBeat·8d ago
News Placeholder
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·8d ago

Latest APLS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.